Angiopreventive versus angiopromoting effects of allopurinol in the XXXX sponge model.

@entity32 @entity66 @entity63 @entity19 @entity1750 @entity641 @entity1317 @entity1611 @entity637 @entity35146 @entity33794
Recent data has indicated that, besides its classical therapeutic indication in hyperurecemia and gout, @entity35146 inhibitors can be used to various forms of @entity63 and other types of tissue and @entity1317 . We tested the hypothesis that allopurinol, an inhibitor of @entity35146 ( @entity35146 ), might modulate acute and/or chronic inflammatory angiogenesis induced by subcutaneous implantation of synthetic matrix in @entity19 . C57/BL6 male @entity19 (6-7 weeks) were implanted with polyether-polyurethane sponge discs. The animals received by oral gavage 1.0mg/kg of allopurinol for six consecutive days in two treatment regimen. In the first series of experiments, the treatment was initiated 24h post-implantation and the implants were removed at day 7 post-implantation. For the assessment of the effect of the compound on @entity32 , the treatment was initiated at day 8 post-implantation and the implants removed 14days post-implantation. Angiogenesis as determined by hemoglobin content, @entity1611 levels and number of vessels intraimplant, and @entity32 (myeloperoxidase -MPO, n-acetyl-b-d-glucosaminidase - @entity33794 , @entity637 and @entity1750 levels) were reduced by allopurinol treatment in acute phase. Similarly, the treatment inhibited nitric oxide and H2O2 production. However, fibrogenesis determined by collagen deposition and levels of @entity641 increased in the implants after allopurinol treatment. In marked contrast with the effects when the treatment initiated 24h post-implantation, allopurinol increased angiogenesis and @entity32 but reduced collagen and @entity641 levels intra-implant, when the treatment was started during the chronic inflammatory process. The dual effects of allopurinol described here, extend its range of actions as a potential agent able to modulate the components of the fibrovascular tissue present in both physiological (healing processes) as well as in chronic @entity66 . These modulatory effects depended on the phase at which the treatment was initiated.
